Procyon says studies show lead drug is safe

New York, Oct. 17 - Procyon Biopharma Inc. said preclinical results for its lead HIV protease inhibitor, PPL-100, show the drug is safe.

Previous studies had shown enhanced bioavailability of the Pro-drug PPL-100 compared to the parent drug, PL-100, and suggested the utility of the drug administered as a potential once daily regimen.

"We are pleased with the solid safety profile of our PPL-100 HIV protease inhibitor as this is a critical issue in the development of such compounds," said Hans Mader, president and chief executive officer of Procyon, in a news release. "Together with the favorable cross-resistance profile, increased bioavailability through the Pro-drug approach, we believe PPL-100 to be a very promising therapy for the treatment of HIV-infection and we are on track to begin clinical trials by year end."

The safety tests were conducted in rats and beagles.

Procyon is a Montreal-based biotechnology company working on therapeutics in the fields of cancer and HIV/AIDS.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.